Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Acquired in-process research and development	$ 0	$ 0	$ 0	$ 500,000
Research and development	4,485,223	2,077,566	12,480,836	4,946,304
General and administrative	1,695,272	1,970,521	5,658,575	6,052,556
Loss from operations	(6,180,495)	(4,048,087)	(18,139,411)	(11,498,860)
Interest income	290,440	192,245	939,256	219,405
Other income	15,369	1,532	5,830	297
Net loss	$ (5,874,686)	$ (3,854,310)	$ (17,194,325)	$ (11,279,158)
Net income (loss) per share - basic (in dollars per share)	$ (0.37)	$ (0.24)	$ (1.08)	$ (0.71)
Net income (loss) per share - diluted (in dollars per share)	$ (0.37)	$ (0.24)	$ (1.08)	$ (0.71)
Weighted average common shares outstanding - basic (in shares)	15,966,053	15,966,053	15,966,053	15,966,053
Weighted average common shares outstanding - diluted (in shares)	15,966,053	15,966,053	15,966,053	15,966,053